These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35352168)

  • 1. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma.
    Shinchi Y; Ishizuka S; Komohara Y; Matsubara E; Mito R; Pan C; Yoshii D; Yonemitsu K; Fujiwara Y; Ikeda K; Tamada K; Sakagami T; Suzuki M
    Cancer Immunol Immunother; 2022 Nov; 71(11):2645-2661. PubMed ID: 35352168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer.
    Yonemitsu K; Pan C; Fujiwara Y; Miyasato Y; Shiota T; Yano H; Hosaka S; Tamada K; Yamamoto Y; Komohara Y
    Sci Rep; 2022 Jul; 12(1):12007. PubMed ID: 35835809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral squamous cell carcinoma cell-derived GM-CSF regulates PD-L1 expression in tumor-associated macrophages through the JAK2/STAT3 signaling pathway.
    Wang P; Tao L; Yu Y; Wang Q; Ye P; Sun Y; Zhou J
    Am J Cancer Res; 2023; 13(2):589-601. PubMed ID: 36895967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma.
    Rong QX; Wang F; Guo ZX; Hu Y; An SN; Luo M; Zhang H; Wu SC; Huang HQ; Fu LW
    Mol Cancer; 2021 May; 20(1):80. PubMed ID: 34051805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
    Horlad H; Ma C; Yano H; Pan C; Ohnishi K; Fujiwara Y; Endo S; Kikukawa Y; Okuno Y; Matsuoka M; Takeya M; Komohara Y
    Cancer Sci; 2016 Nov; 107(11):1696-1704. PubMed ID: 27564404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.
    Wang TT; Zhao YL; Peng LS; Chen N; Chen W; Lv YP; Mao FY; Zhang JY; Cheng P; Teng YS; Fu XL; Yu PW; Guo G; Luo P; Zhuang Y; Zou QM
    Gut; 2017 Nov; 66(11):1900-1911. PubMed ID: 28274999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
    Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
    Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
    Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
    Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma.
    Matsubara E; Shinchi Y; Komohara Y; Yano H; Pan C; Fujiwara Y; Ikeda K; Suzuki M
    Med Mol Morphol; 2023 Dec; 56(4):250-256. PubMed ID: 37402054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.
    Thorn M; Guha P; Cunetta M; Espat NJ; Miller G; Junghans RP; Katz SC
    Cancer Gene Ther; 2016 Jun; 23(6):188-98. PubMed ID: 27199222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
    Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
    Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
    Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
    Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
    Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
    Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-α-dependent lung inflammation upregulates PD-L1 in monocyte-derived macrophages to contribute to lung tumorigenesis.
    Wen Y; Wang X; Meng W; Guo W; Duan C; Cao J; Kang L; Guo N; Lin Q; Lv P; Zhang R; Xing L; Zhang X; Shen H
    FASEB J; 2022 Nov; 36(11):e22595. PubMed ID: 36205325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
    Akbay EA; Koyama S; Carretero J; Altabef A; Tchaicha JH; Christensen CL; Mikse OR; Cherniack AD; Beauchamp EM; Pugh TJ; Wilkerson MD; Fecci PE; Butaney M; Reibel JB; Soucheray M; Cohoon TJ; Janne PA; Meyerson M; Hayes DN; Shapiro GI; Shimamura T; Sholl LM; Rodig SJ; Freeman GJ; Hammerman PS; Dranoff G; Wong KK
    Cancer Discov; 2013 Dec; 3(12):1355-63. PubMed ID: 24078774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
    Han K; Zhang Y
    J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis.
    Saito Y; Fujiwara Y; Shinchi Y; Mito R; Miura Y; Yamaguchi T; Ikeda K; Urakami S; Nakashima Y; Sakagami T; Suzuki M; Tabata Y; Komohara Y
    Cancer Sci; 2022 Sep; 113(9):3255-3266. PubMed ID: 35633190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.